Deepfake equity analysts hint at the future of finance

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Investment banking is a people business. Clients pay generous fees in the hope of getting smart advice from analytical thinkers; relationships are managed deftly by silver-tongued advisers. An experiment by UBS raises the question of … Read more

will China be the first electrostate?

Stay informed with free updates Simply sign up to the Visual and data journalism myFT Digest — delivered directly to your inbox. China could be on its way to becoming the world’s first major “electrostate”, with its electrification rate climbing to 30 per cent, ahead of the EU and US where electricity as a final … Read more

Nvidia unveils major Taiwan chip investments

This article is an on-site version of our FirstFT newsletter. Subscribers can sign up to our Asia, Europe/Africa or Americas edition to get the newsletter delivered every weekday morning. Explore all of our newsletters here Good morning and welcome to FirstFT Asia. On today’s agenda: Nvidia announces major new investment in Taiwan The Trump Organization … Read more

Autonomous cars with ‘social sensitivity’ cut threat to road users, study finds

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Autonomous cars that are trained to respond more like humans to danger will cause fewer injuries during road accidents, according to a study that shows how driverless vehicles might be made safer. Vulnerable groups such … Read more

Microsoft to offer Elon Musk’s xAI models to cloud customers

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Microsoft is making Elon Musk’s start-up xAI’s artificial intelligence models available to its cloud computing customers, in the latest signal of the technology giant’s cooling relations with ChatGPT maker OpenAI. The Seattle-based group said on … Read more

23andMe sold out of bankruptcy to Regeneron

Stay informed with free updates Simply sign up to the Pharmaceuticals sector myFT Digest — delivered directly to your inbox. US drugmaker Regeneron has agreed to buy 23andMe out of bankruptcy for $256mn, ending the genetics testing start-up’s messy run as a public company. The takeover comes less than two months after 23andMe filed for … Read more